Notice bibliographique
Résumé
I was born in Leningrad, Soviet Union in 1951, and have received my B.Sc. in Biology/Biophysics (1971) and M.Sc. in Biochemistry (1973) from the Faculty of Biological Sciences at the Leningrad State University. After receiving my Ph.D. Degree in Molecular Biology and Cancer Biology (1979) from the Petrov Cancer Research Institute, I was continuing my research as a research scientist there. In 1983, I was accepted as a senior research scientist into a newly organized Department of Genetic Engineering at the Institute of Cytology, Leningrad, USSR. In 1990, I immigrated to Israel and started working as an Instructor at the Weizmann Institute of Science, Rehovot, Israel, where I studied the interferon type I receptor signaling at the Department of Molecular Virology under the supervision of Prof. Michel Revel, the leader in cytokine signaling. During my tenure at Weizmann, I was awarded a British Council Award to study in ICI/Zeneca Pharmaceuticals (Alderley Park, UK) allowing me to extend my expertise in yeast genetic engineering. In 1994, I was invited to join the Johns Hopkins University School of (Baltimore, Maryland, USA), as an Assistant Professor of Pathology, where I have developed a strong long-lasting interest in protein-protein interaction studies in cardiovascular and cancer diseases. This approach helped me to discover a novel midkine-dependent signaling pathway, the regulatory proteins affecting the NOS2 activity/dimerization/ degradation, and finally, I have focused on the p63 transcriptional factor implicated in head and neck cancer and ectodermal dysplasia. In 2000, I was promoted to the rank of an Associate Professor of Dermatology/Otolaryngology-Head and Neck Surgery/Oncology and then later to the rank of Professor. Since then my laboratory was able to discover a molecular mechanism underlying ectodermal dysplasia via p63-dependent regulation of RNA splicing for fibroblast growth factor receptor 2, which functions as a key regulator of the epithelial-mesenchymal transition. Since 2004, I have become an Associate Director of Head and Neck Cancer Research Division at the Johns Hopkins. In the same year I have become a member of the Graduate Training Program in Cellular and Molecular at JHMI. In 2008, I have joined the Wilmer Glia Research Laboratory Collaborative Network and Sidney Kimmel Comprehensive Cancer Center and Johns Hopkins Neurofibromatosis Research Center. In 2013, I have also become an Adjunct Professor at the George Washington University (GWIN, SEAS), Washington-DC, USA. To the present date, my collaborative efforts with Drs. David Sidransky and Barry Trink (the researchers who first discovered p53 homologue p63) led to more than 40 international publications, reviews, book chapters and patents on p63 function alone. My name was included in the books 2000 Outstanding Scientists of the 21st Century, Great Minds of the 21st Century and is Who in Medicine (since 2005). I am a Member of the New York Academy of Sciences, International Society on Interferon and Cytokine Research, American Society for Cell Biology, American Association for Cancer Research, International Society for Cell Biology, Society for Investigative Dermatology, American Society for Biochemistry and Molecular Biology, International Society for Stem Cell Research. I am a Member of the Executive Advlsory Board, Biotech/Medical Board, and Sustainability Board of Lifeboat Foundation, and Task Force: Getting to know Cancer. Halifax Project. In 2014-2015, I was awarded a Distinguished Visiting Professorship by an Ecuador Prometeo Foundation and served in the Department of Human Genetics at the La Universidad Tecnica Particular de Loja (UTPL), Loja, Ecuador.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,004 | 0,023 |
| Méta-épidémiologie (sens strict) | 0,002 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,001 |
| Bibliométrie | 0,002 | 0,001 |
| Études des sciences et des technologies | 0,002 | 0,001 |
| Communication savante | 0,009 | 0,005 |
| Science ouverte | 0,002 | 0,003 |
| Intégrité de la recherche | 0,007 | 0,006 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,316 | 0,263 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».